Jefferies resumed coverage on Inozyme Pharma with a new price target

8/13/24 7:33:31 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Jefferies resumed coverage of Inozyme Pharma with a rating of Buy and set a new price target of $17.00 from $16.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INZY

Date	Price Target	Rating	Analyst
12/12/2024	$26.00	Outperform	Raymond James
9/12/2024	$16.00	Buy	Stifel
8/13/2024	$16.00 → $17.00	Buy	Jefferies
5/30/2024	$14.00	Overweight	Wells Fargo
3/23/2023	$4.50 → $6.00	Hold → Buy	Jefferies
5/26/2022	$5.00	Hold	Jefferies
2/7/2022	$33.00	Buy	HC Wainwright & Co.
11/29/2021	$23.00	Buy	Needham